Moderna's COVID-19 Vaccine Found 94.5% Effective | IE

Laverne Higgins
November 17, 2020

Overnight Moderna, one of their competitors, announced that they have one that's nearly 95 percent effective.

The firm's final-stage clinical trial is ongoing and includes more than 30,000 people in the US. Russian Federation said last week its vaccine had 92% efficacy in a large trial. Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID), which collaborated with Moderna.

The UK has secured five million doses of a coronavirus vaccine found to be "94.5%" effective in preventing people from catching Covid-19.

"All the boxes have now been checked", Dr.

Other companies are not far behind Moderna and Pfizer. The company said the efficacy rate could change when more cases are analyzed, but the early numbers surpassed the high bar it had set for preliminary results. That vaccine also remains stable at room temperature for up to 12 hours.

CEO Stéphane Bancel said the company previously thought the shots could only be refrigerated for seven days. Handling some of the shots that are being studied is complicated: For example, Pfizer's must be stored at ultra-cold temperatures until a few days before it is used, a requirement that adds logistical hurdles for states that will be in charge of overseeing the inoculation effort. The government said last week that it had ordered 10 million doses of the BioNTech vaccine, and in August reached a deal with US-based Novavax (NVAX) to purchase 60 million doses and with Johnson & Johnson (JNJ) for 30 million doses. It also struck a $1.5 billion deal to support the manufacturing and delivery of doses.

The world desperately needs a vaccine that can bring the coronavirus down to manageable levels in 2021.

"For those great 'historians, ' please remember that these great discoveries, which will end the China Plague, all took place on my watch!"

Privacy activist files complaints against Apple's tracking tool
The latest complaints by Noyb are based on an old European Union law regulating firms' use of cookies and other tracking devices. Apple was not immediately available for comment when contacted by Business Insider.


Pfizer CEO Albert Bourla said he was "thrilled" to hear about Moderna's progress.

"Our companies share a common goal - defeating this dreaded disease - and today we congratulate everyone at Moderna and share in the joy of their encouraging results", he tweeted.

Approximately 20 million Americans could begin receiving a coronavirus vaccine during the month of December, pending approval by the Food and Drug Administration (FDA) and the recommendation of the Centers for Disease Control and Prevention (CDC), the scientific head of Operation Warp Speed said Monday. Deaths and hospitalizations are also rising. All along, we have known that each day matters.

Moderna expects to manufacture about 20 million doses of the vaccine this year.

Next year, the US Government could have access to more than 1bn doses just from the two vaccine makers, more than needed for its 330m citizens.

Health workers will be immunized first, followed by other essential workers, the elderly and people with high-risk medical conditions. In the vaccinated group, no one got "seriously" ill with COVID.

"People who get offered one should feel quite happy about that", he said.

"While we don't yet have a vaccine, we can now have hope", Mr Hancock said. On Sunday, an independent monitoring board broke the code to examine 95 infections that were recorded starting two weeks after volunteers' second dose - and discovered all but five illnesses occurred in participants who got the placebo. He also said all of the clinical data will be made public.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER